Riskpilot← Back to searchSign inGet full accessJuvenescence AB
ABActiveOrg 5590328174Hörnvägen 5Medical specialists activities · NACE 8622Est. 20151 employees
Revenue 2025
SEK 121K
-21% vs 2024
EBITDA margin
-43.0%
+9% vs 2024
Equity ratio
50.0%
Financial strength
Net profit 2025
SEK -51K
-325% vs 2024
| Revenue | SEK 121K | -21% |
| EBITDA | SEK -52K | +9% |
| Net profit | SEK -51K | -325% |
| Total assets | SEK 24K | -69% |
| Equity | SEK 12K | -81% |
| Employees | 1 | — |
Legal name
Juvenescence AB
Org number
5590328174
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
2 november 2015
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva skönhetsinjektionsbehandlingar med bland annat muskelavslappnande medel och fillers, utförda av legitimerad läkare samt därmed förenlig verksamhet. Vidare skall bolaget även förmedla medicinsk konsultativ verksamhet och uthyrning av läkartjänster samt därmed förenlig verksamhet.
Address
Hörnvägen 5
Email
jpgothenburg@outlook.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 258 | 780 | 287 | 153 | 121 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 160 | 451 | 24 | −57 | −52 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 160 | 451 | 24 | −57 | −52 |
| Net financials | — | −1 | −1 | 1 | 1 |
| Profit before tax | 160 | 450 | 18 | −12 | −51 |
| Tax | −34 | −93 | −4 | −0 | −0 |
| Net profit | 126 | 357 | 14 | −12 | −51 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 311 | 706 | 198 | 77 | 24 |
| Equity | 179 | 411 | 75 | 63 | 12 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 94 | 257 | 79 | 14 | 12 |
| Total debt | 94 | 257 | 79 | 14 | 12 |
EBITDA margin
-43.0%
This company
15.8%
Market median
-372% vs market
20212025
Equity ratio
50.0%
This company
38.2%
Market median
+31% vs market
20212025
Return on equity
-425.0%
This company
18.4%
Market median
-2410% vs market
20212025
Net profit margin
-42.1%
This company
8.1%
Market median
-620% vs market
20212025
Asset turnover
5.04×
This company
1.12×
Market median
+350% vs market
20212025
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Juvenescence AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Joana Pata | Board of Directors | 0 companies |
| Georgia Phaedra Vitali | Board of Directors | 0 companies |